Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1999 2
2003 1
2004 4
2005 1
2006 1
2007 3
2008 3
2009 5
2010 4
2011 8
2012 5
2013 8
2014 10
2015 8
2016 7
2017 6
2018 13
2019 9
2020 8
2021 12
2022 9
2023 9
2024 16
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Mayer-Hamblett N, et al. Among authors: riekert ka. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. Lancet Respir Med. 2023. PMID: 36343646 Free PMC article. Clinical Trial.
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Mayer-Hamblett N, et al. Among authors: riekert ka. Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC. Ann Am Thorac Soc. 2024. PMID: 39041864 Clinical Trial.
Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force.
Hoppe JE, Sjoberg J, Hong G, Poch K, Zemanick ET, Thee S, Edmondson C, Patel D, Sathe M, Borowitz D, Putman MS, Lechtzin N, Riekert KA, Basile M, Goss CH, Jarosz ME, Rosenfeld M. Hoppe JE, et al. Among authors: riekert ka. J Cyst Fibros. 2024 Jul;23(4):725-733. doi: 10.1016/j.jcf.2024.02.011. Epub 2024 Feb 29. J Cyst Fibros. 2024. PMID: 38429150 Review.
Factor analysis: a primer for asthma researchers.
Riekert KA, Eakin M. Riekert KA, et al. J Allergy Clin Immunol. 2008 May;121(5):1181-3. doi: 10.1016/j.jaci.2008.03.023. J Allergy Clin Immunol. 2008. PMID: 18466786 Review. No abstract available.
Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.
Casella JF, Furstenau DK, Adams RJ, Brambilla DJ, Lebensburger JD, Fehr JJ, Jordan LC, King AA, Ichord RN, McKinstry RC, Kraut MA, Shaw DW, White DA, Whyte-Stewart DA, Avadhani R, Barron-Casella EA, Cannon AD, Eaton CK, Riekert KA, Shay JE, Smith-Seidel CA, Weiss DC, Ostapkovich ND, Vermillion K, Treine KE, Kingsbury CE, Strouse JJ, Thompson RE, Hanley DF. Casella JF, et al. Among authors: riekert ka. Am J Hematol. 2024 Oct;99(10):1906-1916. doi: 10.1002/ajh.27423. Epub 2024 Jul 2. Am J Hematol. 2024. PMID: 38953438 Clinical Trial.
Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review.
Eaton CK, McWilliams E, Yablon D, Kesim I, Ge R, Mirus K, Sconiers T, Donkoh A, Lawrence M, George C, Morrison ML, Muther E, Oates GR, Sathe M, Sawicki GS, Snell C, Riekert K. Eaton CK, et al. Among authors: riekert k. JMIR Mhealth Uhealth. 2024 May 1;12:e49024. doi: 10.2196/49024. JMIR Mhealth Uhealth. 2024. PMID: 38717433 Free PMC article. Review.
Social Support, Social Isolation, and Outpatient Cardiac Rehabilitation Participation Among Older Adults in the Community: The ARIC Study.
Mathews L, Mok Y, Ding N, Cudjoe TKM, Riekert KA, Kucharska-Newton A, Coresh J, Benz Scott LA, Stewart KJ, Ndumele CE, Matsushita K. Mathews L, et al. Among authors: riekert ka. J Am Heart Assoc. 2024 May 7;13(9):e033171. doi: 10.1161/JAHA.123.033171. Epub 2024 Apr 30. J Am Heart Assoc. 2024. PMID: 38686871 Free PMC article. No abstract available.
Update on key emerging challenges in cystic fibrosis.
Jennings MT, Riekert KA, Boyle MP. Jennings MT, et al. Among authors: riekert ka. Med Princ Pract. 2014;23(5):393-402. doi: 10.1159/000357646. Epub 2014 Jan 10. Med Princ Pract. 2014. PMID: 24434297 Free PMC article. Review.
American Thoracic Society and National Heart, Lung, and Blood Institute Implementation Research Workshop Report.
Bender BG, Krishnan JA, Chambers DA, Cloutier MM, Riekert KA, Rand CS, Schatz M, Thomson CC, Wilson SR, Apter A, Carson SS, George M, Gerald JK, Gerald L, Goss CH, Okelo SO, Mularski RA, Nguyen HQ, Patel MR, Szefler SJ, Weiss CH, Wilson KC, Freemer M. Bender BG, et al. Among authors: riekert ka. Ann Am Thorac Soc. 2015 Dec;12(12):S213-21. doi: 10.1513/AnnalsATS.201506-367OT. Ann Am Thorac Soc. 2015. PMID: 26653201 Free PMC article. Review.
126 results